Clinical specialities

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #High Content Screening #Imaging #Lead discovery #Molecular medicine #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #System biology #Target validation #Therapeutics

CNS Drug Discovery – Realising the dream

CNS Drug Discovery - Realising the dream By Dr Julie C. Barnes and Dr Ann G. Hayes Over the years, the discovery of drugs for treating neurological and psychiatric diseases has proven to be one of the highest risk areas in the pharmaceutical industry. Despite the huge resources that have… Read More

#Archive

#Animal models #Automation / robotics #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #High Content Screening #Immunology #Lead discovery #Pharmacogenomics #Regulatory #RNA #Theranostics #Toxicology

Theranostics – An emerging tool in drug discovery and commercialisation

By Dr Ian Gilham The increasing cost of healthcare along with new opportunities for improved treatments puts ever increasing pressures on healthcare budgets. In recent years the diagnostic industry in particular has been the target of a number of cost-cutting exercises by governments and payers aimed at restricting the utilisation… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Molecular medicine #PCR #Pharmacogenomics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology

The emergence of pharmacogenomics within the pharmaceutical industry

The emergence of pharmacogenomics within the pharmaceutical industry By Aidan Power, Suzin Webb, Dr Albert Seymour and Dr Patrice Milos The sequencing of the human genome represents one of the most significant scientific advances of the 20th century that will shape the foundation of medical research well into the 21st. Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Patent Law #Pathology #PCR #Pharmacogenomics #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

The importance of using human-based models in gene and drug discovery

The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and to use… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Molecular medicine #Oncology #Protein chemistry / Proteomics #RNA #Screening #Stem cells #Therapeutics #Toxicology

Monoclonal Antibodies – Magic bullets or a shot in the dark

Monoclonal Antibodies - Magic bullets or a shot in the dark By Dr Fiona Adair It has been 16 years since the first monoclonal antibody was approved for therapy in acute transplant rejection. Now, with a further nine therapeutic monoclonal antibodies approved for use and some 16 in phase III… Read More

#Archive

#Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Genetics / genomics #Genomics #High throughput screening #Imaging #PCR #Pharmacogenomics #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Therapeutics

SNP Genotyping in Drug Development

SNP Genotyping in Drug Development By Dr Nicholas C. Dracopoli and Dr Kim E. Zerba SNP-based candidate gene analyses are likely to have a significant impact on predicting drug efficacy and will, undoubtedly, impact on the pharmaceutical industry's development strategies as a whole over the next few years. The human… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Biosecurity #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Pathology #Precision medicine #Regulatory #RNA #System biology #Systems biology

Biotechnology, Bioterrorism & Biosecurity

Biotechnology, Bioterrorism & Biosecurity By Dr George Poste Advances in genetics and biotechnology offer great promise in the fight against infectious diseases. But the same technologies will also increase the threat from bioterrorism. Governments must accord 'biosecurity' a higher priority in defence and foreign policies to reduce the risk of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmokinetics #RNA #Screening #Stem cells #Urinary

Lead Generation and Lead Optimisation: the value of linking HT co-structure analysis and HT chemistry

Lead Generation and Lead Optimisation: the value of linking HT co-structure analysis and HT chemistry By Dr David U Prichard The coupling of High Throughput co-structure analysis with focused library generation is not only proving a powerful general tool in lead optimisation but also increasing the probability of successful discovery… Read More

#Archive

#Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Lead discovery #Lead optimisation #Regenerative Medicine #Regulatory #RNA #Stem cells #Therapeutics

The Future of Cardiovascular Gene Therapy

The Future of Cardiovascular Gene Therapy By Christopher J. Reinhard Advances in regenerative medicine go hand in hand with new perspectives and insights into potential treatments for heart disease. After a decade of pre-clinical and early Phase 1 and 2 clinical studies, gene therapy is now emerging as a genuine… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biochemistry #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Pharmacology #Preclinical #Regulatory #RNA #Stem cells #Toxicology

Obesity – The 21st century disease

Obesity - The 21st century disease By Diane L. McBay and Dr Colin T. Dourish Obesity will be the leading cause of death and disability in the 21st century. This epidemic is largely attributable to increasingly sedentary lifestyles and the abundance of tasty, high-fat foods. Obesity increases the risk of… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Pharmacology #Preclinical #RNA #Screening #Stem cells #Target validation

Channelling Drug Discovery – Current trends in ion channel drug discovery research

Channelling Drug Discovery - Current trends in ion channel drug discovery research By Dr David Owen and Andrew Silverthorne Ion channels are proteins that span cell membranes thus forming conduits or 'channels' through which charged ions such as sodium and potassium can pass across a normally impermeant barrier such as… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #Genomics #High Content Screening #In Silico Biology #Lead discovery #Oncology #Pharmacogenomics #Pharmacology #Regulatory #RNA #System biology #Systems biology #Toxicology

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companiessq

Key R&D informatics challenges facing small/medium-sized pharmaceutical and biotech companies By John Wise The ability of R&D informatics to deliver real benefit to the SME pharmaceutical company is constrained by the increasing burden of non-discretionary computer systems combined with the lack of opportunity to leverage the economies of scale enjoyed… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Gene therapy #Genomics #High Content Screening #Pathology #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology

Metabolism Provides Alternative Door to Stroke Therapy

Metabolism Provides Alternative Door to Stroke Therapy By Dr Keith F. Martin and Tony Dolan Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs. You know that feeling you get the day after an exaggerated attempt at physical… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Automation / robotics #Biochemistry #Cellular & Molecular biology #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High throughput screening #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Organic chemistry #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Proteomics In Drug Target Discovery – High-throughput meets high-efficiency

Proteomics In Drug Target Discovery - High-throughput meets high-efficiency By Dr Terence E. Ryan and Dr Scott D. Patterson Biochemistry is enjoying a renaissance under the guise of 'proteomics' due to the availability of sequenced genomes, advances in mass spectrometry and associated data analysis. Its application to drug discovery and… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Protein chemistry / Proteomics #RNA #Screening #Stem cells

Hit to lead and lead to candidate optimisation using multi-parametric principles

Hit to lead and lead to candidate optimisation using multi-parametric principles By Dr Anthony D. Baxter and Dr Peter M. Lockey As the numbers of potential target proteins become available for pharmaceutical companies of all sizes, the drive towards more cost-effective drug discovery assumes greater significance. It is a truism… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pathology #Pharmacogenomics #Pharmacology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Target validation

The Impact of Genomics on Regulation

The Impact of Genomics on Regulation By Dr Steve Arlington, Dr Tim Peakman, Adriana Salvatore and Jonathan Peachey Advances in science and technology are enabling us to understand physiology and pathology at a totally new level; to define, subtype and track diseases much more accurately; and to treat patients far… Read More

#Archive